PuraMed BioScience -- Starts a Company Marketing Initiative

SCHOFIELD, Wis., May 11, 2009 (GLOBE NEWSWIRE) -- PuraMed Bioscience, Inc.
(OTCBB:PMBS), a pharmaceutical company engaged in the development and marketing
of a line of revolutionary, new, non-prescription medicines targeting major
consumer health needs including the treatment of migraine headaches, insomnia
and tension-type headaches announced today that they will be launching a series
of 8 articles over as many weeks in the Wall Street Journal (WSJ) and the
Investors Business Daily (IBD) newspaper publications.

Our primary objective in launching this marketing campaign is to draw the
attention of U.S. consumers and potential investors to our organization and our
suite of non-prescription drugs that are scheduled to hit the market in the
third quarter of this calendar year. This marketing initiative will commence
over the next 2 months, and management believes it will have a significant
impact on how we are perceived by the investment community and by the public at
large.

The first article will be published on May 11, 2009 in both the Wall Street
Journal and the Investor Business Daily newspapers. Seven more articles will be
published each successive Monday over a consecutive 8-week period. The first
article will provide details on our initial three product offerings along with
the benefits of our sublingual (under the tongue) dosing regiment which will
offer us a serious competitive advantage. These articles can be found within the
Corporate News section of both the WSJ and IBD newspapers. These articles can
also be found on the websites of both the WSJ (2,870,000 newspaper and web
readers) at http://online.wsj.com/home-page and the IBD website (1,692,000
newspaper and web readers) at http://www.investors.com/?tn=top.

These articles will also be published on the websites of Press Method at
http://www.pressmethod.com/ and Equity Feed at http://www.equityfeed.com/, which
are both popular websites dedicated to the individual and institutional
investor. The combined viewership of these two sites is estimated at around
3,000,000 people on the internet.

The articles can also be found at GlobeNewswire at
http://www.globenewswire.com/.

"Our initial products are complete and we are now in the process of implementing
our initial go to market strategy of launching our products to the U.S. consumer
via a direct response television commercial," said CEO Russell Mitchell. "We are
extremely excited about this opportunity to tell our story to millions of
potential investors as well as millions of consumers who can benefit from our
revolutionary new products."

This news release contains forward-looking statements regarding PuraMed
BioScience and its future business plans, which statements involve known and
unknown risks and uncertainties. Such risks and uncertainties may cause actual
results and future achievements of PuraMed BioScience to be materially different
than those implied by these forward-looking statements. PuraMed BioScience has
and undertakes no obligation to provide public updates and revisions to these
forward-looking statements to reflect any changes in its expectations of future
events.

The PuraMed BioScience Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6155

-0-
CONTACT: PuraMed BioScience, Inc.
Russell Mitchell, CEO
715.359.6373
Info@puramedbioscience.com
http://www.puramedbioscience.com